VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

HIV-1 gp120 with mCT E112K
Vaccine Information
  • Vaccine Name: HIV-1 gp120 with mCT E112K
  • Target Pathogen: Human Immunodeficiency Virus
  • Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
  • Vaccine Ontology ID: VO_0004268
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: HIV-1LAIEnv gp120 (Yoshino et al., 2004).
  • Adjuvant:
  • Immunization Route: intranasal immunization
Host Response

Monkey Response

  • Host Strain: rhesus macaques
  • Vaccination Protocol: Rhesus macaques were divided into four groups and nasally immunized with vaccine containing: 1) 100 µg of gp120 alone, 2) 100 µg of gp120 plus 10 µg of nCT, 3) 100 µg of gp120 plus 25 µg of mCT E112K, or 4) 100 µg of gp120 plus 100 µg of mCT E112K. Macaques were anesthetized with ketamine and placed in dorsal recumbancy with head tilted back so that the nares were pointed upward. Vaccine solution (0.5 ml) was instilled dropwise into each nostril without inserting the syringe into the nasal cavity. Macaques were kept in that position for 10 min and then placed in lateral recumbancy until they recovered from anesthesia, as described previously (16). Nasal immunization was conducted on days 0, 7, 14, 28, 42, and 56 (Yoshino et al., 2004).
  • Immune Response: Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4(+)) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups (Yoshino et al., 2004).
  • Host IgA Fc fragment response
    • Description: Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).
    • Detailed Gene Information: Click Here.
  • Host IgG Fc fragment response
    • Description: Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated gp120-specific IgG responses with virus-neutralizing activity in both their plasma and mucosal external secretions compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).
    • Detailed Gene Information: Click Here.
  • Host IL4 response
    • Description: Vaccinated animals that received the adjuvant had a greater increase in IL-4-producing Th2-type CD4-positive (CD4(+)) T cells in mesenteric lymph nodes (MLNs) than did controls vaccinated without the adjuvant, which did not produce IL-4 (Yoshino et al., 2004),
    • Detailed Gene Information: Click Here.
References
Yoshino et al., 2004: Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(11); 6850-6857. [PubMed: 15557179].